Does the use of evantumumab require genetic testing?

Amivantamab (Amivantamab) is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and c-MET receptor. To be used to treat EGFR mutations and c-MET amplified non-small cell lung cancer (NSCLC). Before using evantumumab, it is important to perform genetic testing to ensure its efficacy and safety.

1. EGFR mutation detection: Evantumumab has a significant effect on lung cancer with EGFR mutations. Therefore, genetic testing is used to confirm whether patients have EGFR mutations. Especially for patients who have previously received targeted therapies (such as EGFR tyrosine kinase inhibitors) that have failed, detection of EGFR gene mutations is necessary. The presence of EGFR gene mutations can predict the therapeutic effect of evantumumab because the drug can effectively inhibit the EGFR signaling pathway and exert anti-tumor effects.

2. c-METamplification detection: Evantumumab also inhibits tumor growth by targeting the c-MET receptor. Therefore, patients with c-METamplification may benefit from the use of this drug. Genetic testing can help identify whether patients have c-MET gene amplification or overexpression. c-METAmplification is an important driver in lung cancer and is closely related to cancer progression and drug resistance. By detecting c-METamplification, doctors can assess the suitability of evantumumab as a treatment option.

3. Avoid unnecessary treatment: Through genetic testing, it can be determined which patients are most suitable for evantumumab and avoid those patients whose genetic testing results do not support the drug treatment from receiving ineffective treatment. This not only improves treatment effectiveness, but also reduces unnecessary side effects and waste of medical resources.

In general, when using evantumumab, EGFR mutations and c-METAmplified genetic testing is critical. Genetic testing can help determine whether a patient is a candidate for the drug, maximizing the effectiveness of treatment and ensuring the development of an individualized treatment plan.